|
KMID : 0606920100180040469
|
|
Biomolecules & Therapeutics
2010 Volume.18 No. 4 p.469 ~ p.476
|
|
|
The Promotive Effects of Antioxidative Apigenin on the Bioavailability of Paclitaxel for Oral Delivery in Rats
|
|
Choi Sang-Joon
Choi Jun-Shik
|
|
|
Abstract
|
|
|
|
This study was to investigate the effect of apigenin on the bioavailability of paclitaxel after oral and intravenous administration in rats. The effect of apigenin on P-glycoprotein (P-gp), cytochrome P450 (CYP)3A4 activity was evaluated. The pharmacokinetic parameters of paclitaxel were determined in rats after oral (40 mg/kg) or intravenous (5 mg/kg) administration of paclitaxel with apigenin (0.4, 2 and 8 mg/kg) to rats. Apigenin inhibited CYP3A4 activity with 50% inhibition concentration (IC50) of 1.8 μM. In addition, apigenin significantly inhibited P-gp activity. Compared to the control group, apigenin significantly increased the area under the plasma concentration-time curve (AUC, p＜0.05 by 2 mg/kg, 59.0% higher; p＜0.01 by 8 mg/kg, 87% higher) of oral paclitaxel. Apigenin also significantly (p＜0.05 by 2 mg/kg, 37.2% higher; p＜0.01 by 8 mg/kg, 59.3% higher) increased the peak plasma concentration (Cmax) of oral paclitaxel. Apigenin significantly increased the terminal half-life (t1/2, p＜0.05 by 8 mg/kg, 34.5%) of oral paclitaxel. Consequently, the absolute bioavailability (A.B.) of paclitaxel was significantly (p＜0.05 by 2 mg/kg, p＜0.01 by 8 mg/kg) increased by apigenin compared to that in the control group, and the relative bioavailability (R.B.) of oral paclitaxel was increased by 1.14- to 1.87-fold. The pharmacokinetics of intravenous paclitaxel were not affected by the concurrent use of apigenin in contrast to the oral administration of paclitaxel. Accordingly, the enhanced oral bioavailability by apigenin may be mainly due to increased intestinal absorption caused via P-gp inhibition by apigenin rather than to reduced renal and hepatic elimination of paclitaxel. The increase in the oral bioavailability might be mainly attributed to enhanced absorption in the gastrointestinal tract via the inhibition of P-gp and reduced first-pass metabolism of paclitaxel via the inhibition of the CYP3A subfamily in the small intestine and/or in the liver by apigenin. It appears that the development of oral paclitaxel preparations as a combination therapy is possible, which will be more convenient than the i.v. dosage form.
|
|
|
KEYWORD
|
|
|
Apigenin, Paclitaxal, Bioavailability, Pharmacokinetics, CYP3A4, P-gp, Rats
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|